GLYC Stock Overview
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GlycoMimetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.16 |
| 52 Week High | US$3.53 |
| 52 Week Low | US$1.11 |
| Beta | 2.19 |
| 1 Month Change | -26.28% |
| 3 Month Change | -27.52% |
| 1 Year Change | 46.94% |
| 3 Year Change | -14.62% |
| 5 Year Change | -83.27% |
| Change since IPO | -76.03% |
Recent News & Updates
GlycoMimetics Can Become A Game Changer In Blood Cancers
Mar 21Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Mar 20
Recent updates
GlycoMimetics Can Become A Game Changer In Blood Cancers
Mar 21Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Mar 20GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real
Jan 30Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Nov 19Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?
Jan 30Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely
Oct 06GlycoMimetics has a new Chief Medical Officer
Sep 06GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K
Aug 03GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely
Jun 04GlycoMimetics Positive Data For AML Therapy Increasingly Likely
Mar 16Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Nov 20We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully
Aug 20GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study
May 26Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year
May 12GlycoMimetics EPS beats by $0.04
May 03Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Mar 26GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares
Feb 19GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings
Jan 24How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?
Dec 28New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease
Dec 07Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Dec 07The Investment Case For GlycoMimetics
Nov 17Shareholder Returns
| GLYC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.8% | -4.2% | -3.7% |
| 1Y | 46.9% | -2.0% | 20.5% |
Return vs Industry: GLYC exceeded the US Biotechs industry which returned -1.8% over the past year.
Return vs Market: GLYC exceeded the US Market which returned 20.9% over the past year.
Price Volatility
| GLYC volatility | |
|---|---|
| GLYC Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GLYC's share price has been volatile over the past 3 months.
Volatility Over Time: GLYC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 35 | Harout Semerjian | www.glycomimetics.com |
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein.
GlycoMimetics, Inc. Fundamentals Summary
| GLYC fundamental statistics | |
|---|---|
| Market cap | US$139.21m |
| Earnings (TTM) | -US$36.90m |
| Revenue (TTM) | US$10.00k |
Over9,999x
P/S Ratio-3.8x
P/E RatioIs GLYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLYC income statement (TTM) | |
|---|---|
| Revenue | US$10.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$10.00k |
| Other Expenses | US$36.91m |
| Earnings | -US$36.90m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 100.00% |
| Net Profit Margin | -368,994.20% |
| Debt/Equity Ratio | 0% |
How did GLYC perform over the long term?
See historical performance and comparison